maintenance treatment with thiopurine. This could be inferred from the fact that other maintenance treatments such as biologics should be considered in refractory UC patients treated with high-dose corticosteroids.
The thiopurines, azathioprine and 6-mercaptopurine, have been in clinical use for 50 years. Prospective studies and meta-analyses suggest that thiopurines are effective for the maintenance of remission in UC. 1, 2 By maintaining remission, hospitalization and colectomy rates can be reduced, and long-term complications prevented. However, in the biologic era, the long-term efficacy of thiopurine needs to be better understood. In this issue of Intestinal Research, Yamada et al. tried to assess the long-term efficacy and safety of maintenance treatment with thiopurines in UC. 3 They enrolled a total of 59 bio-naive patients who maintained remission by treatment with thiopurine and 5-aminosalicylate after induction. The cumulative remission-maintenance rates at 24, 48, and 84 months were reported as approximately 69%, 55%, and 44%, respectively. Recent meta-analyses of trial data revealed remission maintenance rates of 56−76% during thiopurine treatment. East Asian patients. 5, 6 Several trials, including this study, have suggested that lower doses of azathioprine or 6-mercaptopurine may be effective and safe for the treatment of UC patients, 7, 8 contrary to the results of Western studies. According to previous studies, approximately 10−28% of patients reported adverse events (AEs), and 25.6% of patients had to discontinue thiopurine therapy due to AEs. 9, 10 A similar rate of AEs (28.8%) was reported in the study by Yamada et al. In this study, the discontinuation rate due to AEs was reported as low as 10.2%, probably due to low thiopurine dose they used. Although there were no severe AEs such as lymphoma and non-melanoma skin cancer in the Yamada et al. study, and the absolute risks of these malignancies remain low, the risks and benefits of continuing or ceasing thiopurine therapy should be weighed for each individual patient. Despite the fact that clinical trials (including the Yamada et al. study) concerning the use of thiopurines for UC have been heterogeneous in design, the evidence is sufficient to conclude that thiopurines are effective for maintenance of remission.
